| Type | Title | Date Released | |
|---|---|---|---|
SCHEDULE 13G | Funk, Stephen P. (Filed by) | ||
8-K/A | Audited 2025 financial statements show revenue rising modestly, net income falling to $9.8 million, and members’ equity increasing to $75.5 million | ||
8-K | Aspire-Lakewood Holdings, Inc. Dismisses Turner Stone & Company and Appoints CBIZ CPAs as New Independent Accountant | ||
8-K | Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program | ||
8-K | Aspire Biopharma Holdings, Inc. Announces Corporate Name Change to Aspire-Lakewood Holdings, Inc. | ||
8-K | Aspire Biopharma Holdings, Inc. Releases Investor Presentation | ||
SCHEDULE 13G/A | HIGHBRIDGE CAPITAL MANAGEMENT LLC (Filed by) | ||
10-Q | Form 10-Q | ||
SCHEDULE 13G | SHIRINYAN GARY (Filed by) | ||
8-K | Aspire Biopharma Completes Acquisition of Dura Driver Control Systems | ||
SCHEDULE 13G/A | Friedman Lance (Filed by) | ||
8-K | Aspire Biopharma Holdings, Inc. Clarifies Terms of Public Warrants Following Reverse Stock Splits |